Edinburgh Molecular Imaging Appoints New Chairman

1 Mar 2023 | Corporate, Events

Edinburgh Molecular Imaging appoints Dr Rob James as Non-Executive Chairman Rob is currently the Managing Partner of Sixth Element Capital and has over 20 years of experience of working in early-stage companies developing oncology drugs. He first worked at Cancer...

Results published by Investigator on identification and validation of MET as target for fluorescent guided surgery in papillary thyroid cancer

11 Apr 2022 | Collaborations, EMI-137

Patients undergoing prophylactic central compartment dissection (PCLND) for papillary thyroid cancer (PTC) are often overtreated. This study aimed to determine if molecular fluorescence-guided imaging (MFGI) and spectroscopy can be useful for detecting PTC nodal...

Results published by Investigator on first-in-human biodistribution and first PET imaging results of [Ga-68]EMP-100 in metastatic renal cell carcinoma

6 Dec 2021 | [Ga-68]EMP-100, Collaborations

This first in‑human biodistribution and imaging study for 68Ga‑EMP‑100 in metastatic renal cell carcinoma independently carried out by LMU Munich, Germany, evaluated uptake characteristics in metastases and primary RCC. Conclusion: Visualization of c-MET expression...

Results published by Investigator on Image-guided Surgery in Penile Squamous Cell Carcinoma Patients

21 May 2021 | Collaborations, EMI-137

This pilot study suggest that c-MET is a promising target for fluorescence-guided tumour identification, with the potential to improve margin assessment in pSCC. The c-MET targeted approach proved to be compatible with lymphatic mapping performed in the same patient...

Results from Phase II clinical development of EMI-137 published

2 Oct 2020 | EMI-137

The work carried ou as part of Phase IIb stage of development of EMI-137 has showed FME using EMI-137 appeared to be safe andfeasible within a 1- to 3-h dose-to-imaging interval. No clinicallysignificant differences were observed among the cohorts, althougha 1-h...